The Diagnostic Role of (18)F-Choline, (18)F-Fluciclovine and (18)F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis.
The Diagnostic Role of (18)F-Choline, (18)F-Fluciclovine and (18)F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis.
复制标题
DOI：
10.3389/fonc.2021.684629
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Tian R
中科院分区：
文献类型：
--
作者：
Wang R;Shen G;Huang M;Tian R
诊断前列腺癌（PCa）的生化复发（BCR）是一项临床挑战，早期检测BCR可以帮助患者接受最佳治疗。我们进行了一项荟萃分析，以确定PET/CT使用18 F标记胆碱、氟鹿昔洛韦和前列腺特异性膜抗原（PSMA）对BCR患者的诊断准确性。截至2021年3月30日，检索了多个数据库。我们纳入了研究18F-胆碱、18F-氟氯烟酸和18F-PSMA PET/CT在BCR患者中的诊断准确性的研究。采用随机效应模型计算18F标记示踪剂的合并灵敏度、特异性和检出率。共有46项研究符合纳入标准;分别有17、16和13项研究关注18 F-胆碱、氟鹿草碱和PSMA。18 F-胆碱和18 F-氟草苷的合并灵敏度分别为0.93（95%CI，0.85-0.98）和0.80（95%CI，0.65-0.897），特异性分别为0.91（95%CI，0.73-0.97）和0.66（95%CI，0.50-0.79）。18F标记的胆碱、氟昔洛韦和PSMA的合并检出率分别为66%、74%和83%。18F标记胆碱、氟硝草碱和PSMA的检出率在PSA <0.5ng/ml时分别为35%、23%和58%，在PSA 0.5- 0.99ng/ml时分别为41%、46%和75%，在PSA 1.0- 1.99ng/ml时分别为62%、57%和86%。PSA水平大于2.0 ng/ml时，分别为80、92和94%。这三种18 F标记的示踪剂有望用于检测前列腺癌患者的BCR，其中18 F-胆碱显示出上级诊断准确性。此外，18F-PSMA的高得多的检出率表明其优于其他示踪剂，特别是在低PSA水平下。PROSPERO，标识符CRD 42020212531。
Diagnosing the biochemical recurrence (BCR) of prostate cancer (PCa) is a clinical challenge, and early detection of BCR can help patients receive optimal treatment. We conducted a meta-analysis to define the diagnostic accuracy of PET/CT using 18F-labeled choline, fluciclovine, and prostate-specific membrane antigen (PSMA) in patients with BCR. Multiple databases were searched until March 30, 2021. We included studies investigating the diagnostic accuracy of 18F-choline, 18F-fluciclovine, and 18F-PSMA PET/CT in patients with BCR. The pooled sensitivity, specificity, and detection rate of 18F-labeled tracers were calculated with a random-effects model. A total of 46 studies met the included criteria; 17, 16, and 13 studies focused on 18F-choline, fluciclovine, and PSMA, respectively. The pooled sensitivities of 18F-choline and 18F-fluciclovine were 0.93 (95% CI, 0.85–0.98) and 0.80 (95% CI, 0.65–0.897), and the specificities were 0.91 (95% CI, 0.73–0.97) and 0.66 (95% CI, 0.50–0.79), respectively. The pooled detection rates of 18F-labeled choline, fluciclovine and PSMA were 66, 74, and 83%, respectively. Moreover, the detection rates of 18F-labeled choline, fluciclovine, and PSMA were 35, 23, and 58% for a PSA level less than 0.5 ng/ml; 41, 46, and 75% for a PSA level of 0.5–0.99 ng/ml; 62, 57, and 86% for a PSA level of 1.0–1.99 ng/ml; 80, 92, and 94% for a PSA level more than 2.0 ng/ml. These three 18F-labeled tracers are promising for detecting BCR in prostate cancer patients, with 18F-choline showing superior diagnostic accuracy. In addition, the much higher detection rates of 18F-PSMA showed its superiority over other tracers, particularly in low PSA levels. PROSPERO, identifier CRD42020212531.
登录
查看更多内容
影响因子：
9.3
作者：
Cimitan, Marino;Evangelista, Laura;Borsatti, Eugenio
通讯作者：
Borsatti, Eugenio
DOI：
10.1016/j.juro.2016.09.117
发表时间：
2017-03
期刊：
The Journal of urology
影响因子：
--
作者：
Bach-Gansmo T;Nanni C;Nieh PT;Zanoni L;Bogsrud TV;Sletten H;Korsan KA;Kieboom J;Tade FI;Odewole O;Chau A;Ward P;Goodman MM;Fanti S;Schuster DM;Willoch F
通讯作者：
Willoch F
DOI：
10.1016/j.juro.2018.08.050
发表时间：
2019-03
期刊：
The Journal of urology
影响因子：
--
作者：
Andriole GL;Kostakoglu L;Chau A;Duan F;Mahmood U;Mankoff DA;Schuster DM;Siegel BA;LOCATE Study Group
通讯作者：
LOCATE Study Group
影响因子：
1.5
作者：
Giovacchini, Giampiero;Giovannini, Elisabetta;Ciarmiello, Andrea
通讯作者：
Ciarmiello, Andrea
影响因子：
6.2
作者：
Filson CP;Natarajan S;Margolis DJ;Huang J;Lieu P;Dorey FJ;Reiter RE;Marks LS
通讯作者：
Marks LS